Johnson & Johnson Tumbles as Medical Device Miss Overshadows Beat

• Our read: EasyAlpha grades Johnson & Johnson B, reflecting good quality that scores better than most healthcare peers in the S&P 500; debt load is its highest-scoring area, while momentum is the main watch item.
• The day: The stock tumbled 5.7% to close at $248.63 after medical device revenue missed expectations, overshadowing stronger pharmaceutical sales and an overall earnings beat.
• Watching: The next scheduled corporate milestone is the fourth-quarter dividend ex-date on November 24, 2026, ahead of payment on December 8, 2026.

Johnson & Johnson tumbled 5.7% on Tuesday, marking the company's largest single-day decline over the past year. Trading volume reached 2.4x its 20-session average as the market responded to third-quarter financial results. On paper, the headline numbers came in ahead of expectations: adjusted earnings of $2.59 per share on revenue of $25.4 billion exceeded Wall Street forecasts. Backed by expanding pharmaceutical revenue, management also raised full-year sales and adjusted profit guidance.

The sharp drop followed unexpected friction in the medical technology division. MedTech sales totaled $8.6 billion, missing Wall Street estimates of $8.71 billion, with international sales remaining flat. Leadership pointed to overseas headwinds, noting that conflict in the Middle East led several governments to shift healthcare budgets toward defense spending. In addition, demand at the Abiomed heart pump unit remained sluggish after a British study raised safety questions regarding Impella pumps. The head of the medical technology division acknowledged that performance was "below the standard we have set internally."

Those MedTech headwinds obscured strong progress in Innovative Medicine, the company's largest segment. Pharmaceutical sales expanded 7.7% to $16.76 billion, lifted by steady oncology demand and a 68% jump in sales for immune disease drug Tremfya to $2.4 billion. That performance helped offset a 54% decline in Stelara revenue following biosimilar competition. Even so, the shortfall in devices raised questions about near-term operational momentum.

EasyAlpha grades Johnson & Johnson B, indicating good quality that scores better than most healthcare peers in the S&P 500. Historically, companies graded A or B have maintained stronger fundamentals and experienced a lower risk of large drawdowns compared to peers graded D or E. The business brought solid underlying metrics into Tuesday's trading, reflected in a profit margin of 21.5% and return on equity of 25.7%. Latest quarterly revenue growth was +6.6% year over year.

The main pressure point for the stock is momentum. Tuesday's pullback brought the stock's one-month move to -6.6%, leaving the shares 11.5% below their 52-week high. Even with Tuesday's drop, the shares trade at a forward price-to-earnings ratio of 21.0. That multiple leaves limited leeway for operational execution to falter. Wall Street analysts remain broadly favorable, with 69.6% of the 23 analysts covering the company rating it a buy. Their average price target of $279.82 implies 12.5% upside from Tuesday's close. Even so, Tuesday showed that when device sales stumble, strong drug results are not enough to prevent a sharp sell-off.